Serotonin 1A receptors in the action of antipsychotic drugs: comment on ‘Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone’ by Frankle et al. 2011; 25(6): 734–743

2012 ◽  
Vol 26 (9) ◽  
pp. 1283-1284 ◽  
Author(s):  
Tomiki Sumiyoshi
Keyword(s):  
Antipsychotic Medication ◽  
Antipsychotic Drugs ◽  
Serotonin 1A Receptor ◽  
Serotonin 1A Receptors

Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review

2000 ◽  
Vol 12 (1) ◽  
pp. 19-26 ◽  
Author(s):  
H. Knegtering ◽  
P.A. Lambers ◽  
G. Prakken ◽  
C. ten Brink
Keyword(s):  
Antipsychotic Medication ◽  
Antipsychotic Drugs ◽  
University Hospital ◽  
Serum Prolactin ◽  
Sexual Dysfunctions ◽  
Receptor Blockade ◽  
Naturalistic Study ◽  
Serotonergic Receptor ◽  
Male Patients ◽  
The University

SUMMARYClassical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to increase the risk of erectile and ejaculatory disorders in male patients and to menstrual disturbances in female patients. In the literature reviewed, risperidone is associated with higher prolactin levels in comparison to classical antipsychotics. It is still unclear which mechanism is responsible for the increase of serum prolactin levels and sexual dysfunctions in patients using risperidone. Dopaminergic and serotonergic receptor blockade seems to play an important role. Other mechanisms are discussed.

scholarly journals High-dose antipsychotic medication

1996 ◽  
Vol 20 (11) ◽  
pp. 676-680 ◽  
Author(s):  
Peter L. Cornwall ◽  
Fuad Hassanyeh ◽  
Caprice Horn
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Clinical Practice ◽  
Antipsychotic Medication ◽  
Antipsychotic Drugs ◽  
Maximum Dose ◽  
High Dose ◽  
National Formulary ◽  
Physical Status ◽  
High Dose Treatment

We audited the use of high-dose antipsychotic drugs in patients admitted to a special (intensive) care unit over two periods. Five out of 57 patients in the first sample and three out of 62 in the second were treated with a single antipsychotic drug above the British National Formulary maximum dose. The proportion of patients treated with antipsychotic drugs such that the total dose in chlorpromazine equivalents was greater than 1000 mg, fed. The audit showed improvements in clinical practice, particularly with respect to the onset of, indication for and outcome of high-dose treatment and in monitoring the patients' physical status.

scholarly journals Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used

2010 ◽  
Vol 197 (1) ◽  
pp. 67-72 ◽  
Author(s):  
Alison Pope ◽  
Clive Adams ◽  
Carol Paton ◽  
Tim Weaver ◽  
Thomas R. E. Barnes
Keyword(s):  
Adverse Effects ◽  
Antipsychotic Medication ◽  
Clinical Studies ◽  
Antipsychotic Drugs ◽  
Rating Scales ◽  
Primary Source ◽  
Subjective Experiences ◽  
Schizophrenia Group ◽  
Tolerability Data ◽  
Definition Of

BackgroundClinical studies of antipsychotic medication are a primary source of data on the nature of, and relative liability for, adverse effects, relevant to prescribing decisions in clinical practice.AimsTo identify how safety and tolerability data were collected and reported in recent clinical studies of antipsychotics.MethodA survey was conducted of all 167 eligible studies published between 2002 and 2007 on the Cochrane Schizophrenia Group register.ResultsExtrapyramidal side-effects (EPS) and weight gain were most frequently assessed. A minority of reports addressed metabolic abnormalities, aversive subjective experiences and sexual dysfunction. Published rating scales were frequently used to evaluate EPS, but systematic methods were rarely applied to other treatment-emergent problems. The definition of individual adverse effects and the manner of reporting were inconsistent.ConclusionsThe way in which safety and tolerability data are collected and reported in clinical studies does not allow for fair and meaningful comparison of the relative risk profiles of individual antipsychotic drugs.

Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone

2010 ◽  
Vol 25 (6) ◽  
pp. 734-743 ◽  
Author(s):  
W Gordon Frankle ◽  
Ilise Lombardo ◽  
Lawrence S Kegeles ◽  
Mark Slifstein ◽  
John H Martin ◽  
...  
Keyword(s):  
Antipsychotic Medication ◽  
Serotonin 1A Receptor

scholarly journals RECURRENT TEMPOROMANDIBULAR JOINT DISLOCATIONS IN GERIATRIC PATIENT ON ANTIPSYCHOTIC DRUGS AND ITS CONSERVATIVE MANAGEMENT

2017 ◽  
Vol 10 (11) ◽  
pp. 8 ◽  
Author(s):  
Deepika Pai ◽  
Abhay Kamath T ◽  
Girish Menon ◽  
Arun Urala ◽  
Saurabh Kumar ◽  
...  
Keyword(s):  
Temporomandibular Joint ◽  
Antipsychotic Medication ◽  
Conservative Management ◽  
Antipsychotic Drugs ◽  
Recurrent Dislocation ◽  
Oromandibular Dystonia ◽  
Tmj Dislocation ◽  
Joint Dislocations ◽  
Patient Reported ◽  
Systemic Condition

  Recurrent temporomandibular joint (TMJ) dislocation can cause difficulty in swallowing and speech hence can be distressing for the patient. A 79-year-old male patient reported with recurrent dislocation of TMJ since 2 months. He was on antipsychotic medication for schizophrenia which predisposes to recurrent TMJ dislocation due to oromandibular dystonia. Since the patient had undergone tracheostomy, his systemic condition was not suitable for surgical management. Thus a conservative option of chin cup was planned. The chin cup limits the movement of the mandible hence prevents dislaocation of the TMJ. The patient was successfully rehabilitated with no new episodes of TMJ dislocation for the last 4 months. It focuses on conservative management of recurrent TMJ dislocations induced by antipsychotic drugs.

The spectrum of subjective effects of antipsychotic medication

2003 ◽  
Vol 15 (5) ◽  
pp. 274-279 ◽  
Author(s):  
Hugo A Wolters ◽  
Rikus Knegtering ◽  
Durk Wiersma ◽  
Robert J van den Bosch
Keyword(s):  
Atypical Antipsychotic ◽  
Antipsychotic Medication ◽  
Antipsychotic Drugs ◽  
Subjective Effects ◽  
Interview Data ◽  
Subjective Experiences ◽  
Atypical Antipsychotic Drugs ◽  
Psychological Domain

Background:This study examined the spectrum of subjective experiences which patients attribute to the use of antipsychotic medication.Methods:We collected interview data and answers to structured questions based on a comprehensive checklist in 77 patients using various types of classical or atypical antipsychotic drugs.Results:The responses of the patients could be categorized into psychological and somatic domains. The psychological domain could be subdivided into emotional, cognitive and sociability domains. The somatic set could be subdivided into activation and physiological domains.Conclusions:Our data reveal that the same effects may be experienced in either a positive or a negative way by different patients. We conclude that existing scales for measuring subjective effects of antipsychotic medication are incomplete.

Homozygous mutation at cytochrome P4502D6 in an individual with schizophrenia: Implications for antipsychotic drugs, side effects and compliance

1997 ◽  
Vol 14 (1) ◽  
pp. 38-39 ◽  
Author(s):  
Michael Gill ◽  
Ziarih Hawi ◽  
Marcus Webb
Keyword(s):  
Side Effects ◽  
Antipsychotic Medication ◽  
Antipsychotic Drugs ◽  
Homozygous Mutation ◽  
Cyp2d6 Gene ◽  
Rational Prescribing

AbstractWe report the case of a patient with schizophrenia who has suffered severe side effects with many different antipsychotics. She is poorly compliant with treatment probably because of her experiences with medication. We determined her genotype at the CYP2D6 gene that codes for an enzyme principally involved in the metabolism of many antipsychotics. She was homozygous for the ‘B’ mutation, the most frequent of several known mutations. She therefore has no functioning CYP2D6 enzyme in common with 5%-10% of the population. This may explain why she is sensitive to quite moderate doses of antipsychotic medication, and more rational prescribing may lead to fewer side effects and increased compliance.

Sign in / Sign up

Export Citation Format

Share Document